PKD Cures Act
Sponsored By: Representative Wasserman Schultz, Debbie [D-FL-25]
Introduced
Summary
A coordinated, technology-enabled effort to speed research into polycystic kidney disease (PKD). This bill would amend the Public Health Service Act to require the NIH Director to expand and prioritize basic, translational, and clinical PKD research and to push collaborations that accelerate new treatments and training for clinicians and researchers.
Show full summary
- Patients and families: Could see faster movement from lab discoveries to clinical trials and potential new therapies as research priorities are focused and public and private partners coordinate.
- Researchers and clinicians: Would gain clearer priority-setting, support for training programs to build PKD expertise, and incentives to collaborate across Federal agencies, universities, and industry.
- Federal coordination and oversight: NIH must create a working group with PKD experts and patient advocates to produce a comprehensive PKD roadmap, recommend milestones and public-private strategies, integrate tools like artificial intelligence and precision medicine, and report its findings to Congress within 24 months.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More PKD research and training
If enacted, this bill would require the Institute Director to expand research on polycystic kidney disease (PKD). Research would cover basic, translational, and clinical studies to find causes, biomarkers, and treatments. The Director would work with federal agencies, universities, and private groups. The Director would prioritize research proposals with clear potential and would support training programs to build a PKD research and clinical workforce. These changes would take effect upon enactment and do not set a specific funding amount.
Sponsors & CoSponsors
Sponsor
Wasserman Schultz, Debbie [D-FL-25]
FL • D
Cosponsors
Rep. Miller, Carol D. [R-WV-1]
WV • R
Sponsored 6/4/2026
Rep. Cleaver, Emanuel [D-MO-5]
MO • D
Sponsored 6/4/2026
Rep. Bacon, Don [R-NE-2]
NE • R
Sponsored 6/4/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov